The number of CD34 ؉ cells collected during apheresis is related to the volume of blood processed. In largevolume apheresis (LVL) procedure, more cells can be collected than were originally present in the peripheral blood at the start of the collection procedure. We prospectively studied the levels of CD34
platelet recovery, and reduced platelet and red blood cell transfusion requirements. Rapid and sustained engraftment following high-dose therapy can be predicted by the quantity of hematopoietic stem and progenitor cells infused. 1, 2 We and others have previously demonstrated that the concentration of CD34 ϩ cells in the peripheral blood closely correlates with the yield of CD34 ϩ cells collected by apheresis. [3] [4] [5] Collection efforts are geared towards mobilizing and harvesting as many CD34
ϩ cells (a surrogate measure of stem cell quantity) as possible. Sufficient cells for transplantation can often be collected in a single apheresis procedure if high levels of CD34
ϩ cells are present in the peripheral blood. 3 However, for patients with low levels of HSC reserves as a consequence of previous chemotherapy or radiotherapy or involvement of the marrow in the disease process, 6 the processing of larger amounts of blood through multiple apheresis procedures may be necessary to achieve the desired number of CD34 ϩ cells. Alternately, larger volumes of blood can be processed per procedure, a technique called large volume leukapheresis (LVL).
LVL is not defined, but in general usage refers to processing more than two or three times the patient's total blood volume (BV), and typically, six or more times the BV in a single apheresis session. [7] [8] [9] [10] [11] [12] The advantage of LVL is that a greater quantity of blood can be processed in fewer days, thereby reducing the costs of cytokine administration and laboratory processing and testing. LVL is feasible only if the level of CD34 ϩ cells in the blood is maintained throughout the apheresis procedure. Several investigators have reported the collection of more CD34 ϩ cells with LVL than were calculated to be present in the peripheral blood at the initiation of the collection procedure. [9] [10] [11] [12] Consequently, CD34 ϩ cells removed during the apheresis procedure must be replaced by others released from reservoirs of these cells, presumably the bone marrow. This clinical observation, as well as the demonstration of increased blood levels of HSC in studies involving humans and animals not treated with cytokines, [13] [14] [15] [16] led some authors to suggest that CD34 ϩ cells are recruited into the peripheral blood as a consequence of the LVL procedure itself, 11, 12 although other investigators reported an exhaustion of CD34 ϩ cells in the peripheral blood during or after LVL. 17 This study was designed to explore the kinetics of CD34 ϩ cell release from the bone marrow or other reservoirs during the apheresis procedure. Multiple samples of blood were obtained at intervals during the apheresis pro-cedure in order to calculate the quantity and rate that these cells were released and to determine if apheresis collection techniques affected the trafficking of these cells between marrow and peripheral blood.
Methods

Patient population
This is a prospective analysis of large-volume apheresis procedure outcome for patients undergoing PBSC collection in anticipation of autologous transplantation. Patients eligible for this study were those with a diagnosis of multiple myeloma or acute myeloblastic leukemia and age over 18 years. Protocols for PBSC mobilization and collection were approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Informed consent for the collection of PBSC by LVL and the additional testing required for this study was obtained from all patients.
Mobilization regimen
Mobilization regimens used in this study (Table 1) 2 ) with (n ϭ 2) or without (n ϭ 5) dexamethasone 10 mg four times daily p.o. for 4 days (total dose, 160 mg). 18 Cells from two patients with AML were collected during the recovery phase of consolidation regimens that included a Shown is median (range). AML ϭ acute myeloid leukemia; MM ϭ multiple myeloma; BV ϭ patient's blood volume; WB ϭ whole blood; Cy ϭ cyclophosphamide; Tax ϭ paclitaxel; VP16 ϭ etoposide; Ara-C ϭ cytosine arabinoside. Mobilization regimens are described in detail in Methods; all chemotherapy-based mobilization regimens also included cytokine administration.
cytosine arabinoside. All chemotherapy-treated patients received filgrastim (Amgen, Thousand Oaks, CA, USA) at a dose of 10 g/kg/day by subcutaneous injection until the completion of the collection procedures. Apheresis procedures were initiated for patients treated with chemotherapy-containing regimens when the peripheral blood white blood cell count exceeded 1 ϫ 10 9 /l. Patients who previously failed chemotherapy mobilization and patients in remission who would not benefit from treatment with chemotherapy-based mobilization regimens were treated with filgrastim (10 g/kg/day (n ϭ 4) or 16 g/kg/twice a day (n ϭ 2)) or sargramostim (1000 g/kg/day; n ϭ 1) alone with apheresis procedures started on the fourth day of cytokine administration.
Collection of PBSC
A central venous catheter was used for venous access for all patients studied. Leukapheresis was performed with the use of continuous flow blood cell separator (Spectra, version 4.7; COBE BCT, Engelwood, CO, USA). The target volume of blood to be processed during the apheresis procedure was six times the patient's calculated blood volume (BV), which was determined from apheresis device nomograms based on patient height, weight and gender. Anticoagulant solution, consisting of 10 units of heparin per ml of ACD-A, was infused at a ratio of 1 ml anticoagulant to 30 ml whole blood. An additional 40 ml of this anticoagulant mixture was placed in the collect bag before the initiation of the apheresis procedure. Inlet flow rate was maintained at 100 ml per minute or less for the first seven patients enrolled on the study. A higher inlet flow rate (up to the machine maximum of 150 ml/min) was allowed for subsequent patients but limited to an anticoagulant infusion rate not exceeding 0.8 ml per liter of patient BV per minute. Decreases in the inlet flow rates were made according to catheter function and patient tolerance. The collection rate was maintained at 1 ml per minute. The criterion for adequate PBSC collection was a target number of 5 ϫ 10 6
CD34
ϩ cells/kg. Leukapheresis was continued daily in an attempt to achieve the goal, although only one LVL procedure with extensive blood sampling was allowed for this study. Samples of the peripheral blood were obtained for quantification of mature blood cells and CD34 ϩ cells at the initiation of the procedure, and after processing of blood equivalent to 1, 2, 4 and 6 BV (end of procedure). Samples were also obtained from the collection line of the apheresis device and the PBSC component at the same intervals (excluding the initiation of the procedure).
Collection efficiency for the various cell populations studied at the specific intervals studied was calculated by dividing the product of the concentration of cells in the collect line and the collect rate by the product of the concentration of cells in the peripheral blood and the whole blood flow rate.
Laboratory evaluation of blood and PBSC components
CD34
ϩ cell counts were performed as previously described. 19 In brief, a sample of 1 ϫ 10 6 nucleated cells were stained with phycoerythrin (PE)-conjugated anti-CD34 stain (HPCA-2; Becton Dickinson, San Jose, CA, USA) and fluorescein isothiocyanate (FITC)-conjugated antibody to CD14 (Leu-M3; Becton Dickinson) added at the concentrations recommended by the manufacturer after lysis of red blood cells using ammonium chloride. Control samples consisted of the same cell quantity incubated with PE-conjugated IgG 1 (Becton Dickinson) in conjunction with the CD14 stain. The cells were analyzed using a FACScan flow cytometer (Becton Dickinson) and 100 000 events acquired. Listmode data were analyzed using Winlist software (Verity Software House, Topsham, ME, USA). 'Bright' CD34 ϩ cells were defined with histogram analysis using simultaneous gates first established on nucleated cells (defined by forward and orthogonal light scatter characteristics) and CD14-negative cells (defined by low orthogonal light scatter and lack of CD14 staining). The percentage of viable CD34
ϩ cells was calculated after subtraction of the number of cells showing non-specific staining in the isotypic control sample. The absolute number of CD34 ϩ cells was obtained by multiplying the percentage of CD34 ϩ cells by the cell count and volume of the specimen. Peripheral blood cell counts were determined using a Sysmex NE 8000 (Sysmex Corporation of America, Long Grove, IL, USA). WBC counts in the apheresis components were obtained using a Sysmex NE 2500. Cell differentials were manually performed on Wright Giemsa-stained specimens and the number of mononuclear cells (MNC, defined as lymphocytes and monocytes) was calculated.
Statistical analysis
Patient characteristics and LVL outcome data are summarized using medians and ranges unless otherwise described. Examinations of the differences in collection efficiencies as a function of several explanatory variables (6 BV vs other time points, AML vs myeloma, chemotherapy plus cytokine mobilization vs cytokine alone) were studied in regression models using generalized estimating equations, which account for intra-patient correlations that may exist as a result of the multiple sample points from individual patients. Except for analysis of collection efficiency at each time point, for which the data were limited to the time points being analyzed, data collected for all time points were used for analysis of other variables. Both univariable and multivariable models were examined; multivariable models included all variables examined even if the variables were not statistically significant or suggestive of an association in the univariable models. Confidence intervals were also calculated. A P value of Ͻ0.05 is considered significant. All P values reported are two-sided.
We excluded from analyses of CD34 ϩ cell collection efficiency the data for three patients for whom the starting peripheral blood level of CD34 ϩ cells was Ͻ10 ϫ 10 6 /l because of the inherent error in measuring low numbers of these cells. 20 Data from these procedures were included in the analysis of collection efficiency for the other cell types studied.
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Results
Patient demographics are shown in Table 1 . The blood volume for these 21 patients and the amount of blood processed during the collection procedure averaged 5.1 l and 30.7 l, respectively. For the first seven patients, the LVL procedures were performed at whole blood flow rates limited to 100 ml/min. For the subsequent patients, whole blood flow rates up to 150 ml/min were allowed, restricted to an anticoagulant infusion rate of 0.8 ml/l BV/min. Despite the large volume of blood processed, the high blood to anti-coagulant ratio used reduced the amount of anti-coagulant solution infused. Only two patients complained of symptoms of citrate toxicity, which were alleviated by oral calcium supplementation and a decrease in whole blood flow rates. None of the procedures was discontinued before the target volume of blood was processed. The average duration of the procedures was 281 min.
The median counts of various cell populations in the peripheral blood, in the collect line, and in the product during the procedures are shown in Table 2a -c. A general decline in the quantity of peripheral blood cells occurred during the apheresis procedure. The drop in these cells was most evident shortly after the initiation of the apheresis procedure, as cells were packed into the blood channel of the apheresis device, with a gradual subsequent decline ( Figure  1 ). This decline was minimal for total nucleated cells (WBC) and granulocytes; platelets and CD34 ϩ cells fell to an average (Ϯ s.d.) of 47.5 Ϯ 12.9% and 42.3 Ϯ 22.0%, respectively, of the values at the start of the procedure. For none of the apheresis procedures was there a higher level of CD34 ϩ cells in the peripheral blood at the completion compared to the start of the run.
The quantity of CD34 ϩ cells collected during the LVL procedures exceeded the quantity of these cells calculated to have been present in the peripheral blood at the start of the procedure by an average (Ϯs.d.) of 3.0 Ϯ 1.1-fold. The larger numbers of CD34 ϩ cells collected than what were present in the peripheral blood indicates a release from other reservoirs of these cells during the apheresis procedure, although the falling peripheral blood concentrations show that the release was somewhat slower than the rate of removal by the apheresis device. The collection of mononuclear cells was similarly greater (3.9 Ϯ 2.1-fold). However, the total number of granulocytes and platelets collected was less than the total amount in the peripheral circulation at the start of the procedure, averaging only 55.3 Ϯ 57.9% and 74.8 Ϯ 15.9%, respectively, of the initial number of cells in the peripheral blood. The difference in this ratio of cells collected for platelets or for mononuclear or CD34
ϩ cells despite similar percentage falls in peripheral blood counts for all three cell types ( Figure 1 ) is a result of the lower collection efficiency for platelets compared to the desired CD34 ϩ cells (Table 3) , but also indicates, because the falls in peripheral blood levels were not more pronounced, a greater release from other reservoirs of mononuclear cells and CD34 ϩ cells during the procedure. The data from three apheresis procedures (all for patients with AML) were excluded from calculation of the release of CD34 ϩ cells and CD34 ϩ cell collection efficiency because the concentration of these cells in the peripheral (Table 2a) were calculated from the number of cells per liter and the patient's total blood volume. Total numbers of cells in the apheresis component (Table 2c) were calculated from the number of cells per liter and the component volume at each time point. The time points indicated refer to the number of times the patient's blood volume was processed, with the apheresis procedure stopped after the processing of blood equal to six times the patient's blood volume. BV ϭ blood volumes processed; WBC ϭ total nucleated cells; MONO ϭ lymphocytes and monocytes; GRAN ϭ nucleated cells other than lymphocytes and monocytes; PLT ϭ platelets; CD34 ϭ CD34 ϩ cells.
blood at the start of the collection procedure was less than 10 ϫ 10 6 /l, a level below which there is limited precision of measurement. 20 The calculated release of CD34 ϩ cells during the apheresis procedure averaged 3.71 ϫ 10 6 /min (median, 2.83 ϫ 10 6 /min; range, 0.36-13.7 ϫ 10 6 /min), and correlated with the number of CD34 ϩ cells in the peripheral blood at the initiation of the procedure (Figure 2a-d) . Similarly, the calculated release of mononuclear cells and platelets also correlated with the numbers of these cell populations in the peripheral blood at the start of the apheresis procedure. The negative correlation between granulocytes in the peripheral blood and the calculated rate of release indicates a shift of granulocytes from the peripheral circulation into other reservoirs such as the marrow or spleen that was most pronounced for patients with the highest peripheral blood counts at the start of the collection.
The efficiency of collection (proportion of cells collected during each pass through the apheresis device) of the apheresis device for CD34 ϩ cells averaged 92.6 Ϯ 47.1% (Ϯ s.d.; median, 84.1%; range, 15.6-356.2%; calculated using data for all time points but excluding three patients with low peripheral blood CD34 + cell numbers as stated above). The efficiency of collection for CD34 ϩ cells, mononuclear cells, and platelets remained constant at the various time points measured during the apheresis procedure (Table 3) . Diagnosis, mobilization regimen, and whole blood flow rate also were not prognostic factors for the efficiency of collection of CD34 ϩ cells in either univariable or multivariable Shown are the median collection efficiencies for the various peripheral blood cells listed, categorized by various patient and apheresis technique variables.
In the parentheses are the estimated difference from the mean of the baseline variable (first variable for each category studied) and the 95% confidence interval for this difference. Data obtained for all time points were used for analysis of variables other than 'time point', for which only the data for the two time points being compared were entered into the analysis. Only the three comparisons of granulocyte collection efficiency indicated by an asterisk differed significantly from the respective baseline variable (P Ͻ 0.05). BV ϭ blood volume; AML ϭ acute myelogenous leukemia; MM ϭ multiple myeloma; chemo ϭ chemotherapy plus filgrastim for mobilization; cytokine ϭ filgrastim alone for mobilization. See legend of Table 2 for description of cell type abbreviations. Figure 1 Shown are the average percents of initial values for peripheral blood cell counts at various points during the apheresis procedure. Time points indicated on the x-axis refer to amount of blood processed in terms of the patient's blood volume (BV). Procedures were completed after the processing of 6 blood volumes. Abbreviations used are the same as in Table 2 . (Table 4) analysis. Granulocyte collection efficiency increased towards the completion of the procedure and was greater for patients with the diagnosis of myeloma in both univariable and multivariable analyses.
Discussion
These data support the widely held belief that more CD34 ϩ cells can be collected in an apheresis procedure if the volume of blood processed is increased. The major risks of LVL are the greater time commitment, exposure to citrate anti-coagulants, and loss of platelets that averages, at our center, 10% for each BV processed. Our data show that the increased time commitment required by LVL can be offset by the processing of blood at higher blood flow rates withBone Marrow Transplantation out a loss in collection efficiency and without increased citrate toxicity if modified anticoagulant solutions are used.
We found neither a major increase in the numbers of CD34 ϩ cells in the peripheral circulation nor an exhaustion of these cells for the limited number of patients enrolled in this study. Rather, our data show a modest decline in CD34 ϩ cell levels in the peripheral blood through the procedure. The more rapid fall at the initiation of the procedure is, presumably, a result of the packing of the blood pathway of the apheresis device. Subsequently, there is a slow fall in blood levels as most (about 90%) of the CD34 ϩ cells are removed during each pass through the device. These data do not support recruitment of these cells into the blood as a direct or indirect consequence of the apheresis procedure. Instead, we found a falling level of all cell types in the blood that were measured.
Our data demonstrate a relationship between the level of CD34 ϩ cells in the peripheral blood at the start of the apheresis procedure and the number of these cells being released from other reservoirs such as the bone marrow over the period during which apheresis is performed. A more precise measurement of cell kinetics would require labeling of cells in some manner with serial sampling of peripheral blood and bone marrow to demonstrate the trafficking of these cells between these compartments. However, an obvious corollary to this finding is that, in the absence of a very rapidly rising number of these cells in the peripheral blood, approximately similar numbers of these cells are also exiting the blood to return to the marrow space. Thus, to increase the effectiveness of mobilization of HSC requires an increase in the level of cells in the other reservoirs and the transiting of these cells between those reservoirs and the peripheral blood. This observation and the unchanging collection efficiency of the apheresis device during the apheresis procedure indicate that apheresis is Tables 2 and 3 for explanation of abbreviations.
unlikely to be a direct cause of release of these cells from other reservoirs in the setting of cytokine mobilization. The apheresis device instead acts as a siphon of these cells from the blood. This raises the possibility that extensive processing of blood could deplete the cell of interest from these other reservoirs if the rate of production is not equivalent to the rate of release and collection, although this was not observed in this study. Furthermore, processing of larger blood volumes would be of limited utility if CD34 ϩ cells were not continually released from the other reservoirs.
We did not observe an increase in the level of CD34 + cells in the peripheral blood during the apheresis procedure. This is in contrast to reports of apheresis of animals and humans not treated with hematopoietic cytokines to mobilize these cells into the peripheral blood in whom rising levels of HSC were found in the peripheral blood during the procedure. [13] [14] [15] [16] The potential explanation of this difference is that the release of cells from the marrow (or other potential reservoirs) as a direct result of stress from apheresis or from the infusion of citrate is overwhelmed in the setting of cytokine administration. We did not attempt to quantify CD34 ϩ cells in the bone marrow before or after the apheresis procedure. Presumably, the marrow is the primary reservoir of CD34 ϩ cells and the administration of cytokines affects both the number of these cells and the trafficking of these cells into the peripheral blood. Thus, improvement in PBSC collection requires increased marrow reservoirs of HSC and increased trafficking of these cells into the peripheral circulation, which may be achieved with improved or novel cytokine or chemokine regimens.
This study ignores the changes in blood levels of these cells that occur as a consequence of cytokine pharmacokinetics. We did not measure in a serial manner the period between cytokine administration and apheresis or the subsequent period after completion of the collection procedure. The negative correlation between the peripheral blood granulocyte concentration and the release of these cells into the peripheral blood suggest that the patients with the highest levels of these cells experienced a net migration out of the peripheral circulation. This may be a consequence of filgrastim pharmacokinetics with more dramatic fluctuations in granulocyte levels during the period between filgrastim doses. Few studies have reported the kinetics of CD34 ϩ cell release relative to the timing of filgrastim administration. 21 Techniques such as reported in this study that measure the rate of cells released into the peripheral circulation allow exploration of mobilization techniques to maximize the yield of cells and minimize the cost of PBSC harvesting. Our demonstration of a correlation between the peripheral blood concentration of CD34 ϩ cells and the rate of release of these cells from the marrow greatly simplifies such studies.
